K D Crew, G L Anderson, K B Arnold, A P Stieb, J N Amenta, N Collins, C W Law, S Pruthi, A Sandoval-Leon, D Bertoni, M T Grosse Perdekamp, S Colonna, S Krisher, T King, L D Yee, T J Ballinger, C Braun-Inglis, D Mangino, K B Wisinski, C A DeYoung, M Ross, J Floyd, A Kaster, L Vander Walde, T Saphner, C Zarwan, S Lo, C Graham, A Conlin, K Yost, D Agnese, C Jernigan, D L Hershman, M L Neuhouser, B Arun, R Kukafka
INTRODUCTION: Women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) have a significantly increased risk of breast cancer, which can be substantially reduced with antiestrogen therapy for chemoprevention. However, antiestrogen therapy for breast cancer risk reduction remains underutilized. Improving knowledge about breast cancer risk and chemoprevention among high-risk patients and their healthcare providers may enhance informed decision-making about this critical breast cancer risk reduction strategy...
May 2, 2024: Contemporary Clinical Trials